Document is current
Any future updates will be listed below
-
Authors
Fraser, Douglas D.
Van Nynatten, Logan R.
Tweddell, David
Daley, Mark
Russell, James A.
,
Tran, Karen C.
Asfar, Pierre
Cheng, Matthew P.
Demiselle, Julien
Singer, Joel
Lee, Terry
Sweet, David
Boyd, John H.
Walley, Keith R.
Haljan, Greg
Geri, Guillaume
Auchabie, Johann
Quenot, Jean-Pierre
Lee, Todd C.
Tsang, Jennifer
Meziani, Ferhat
Lamontagne, Francois
Dubee, Vincent
Lasocki, Sigismond
Ovakim, Daniel
Wood, Gordon
Turgeon, Alexis F.
Cohen, Yves
Lebas, Eddy
Goudelin, Marine
Forrest, David
Teale, Alastair
Mira, Jean-Paul
Fowler, Robert
Daneman, Nick
Adhikari, Neil K. J.
Gousseff, Marie
Leroy, Pierre
Plantefeve, Gaetan
Rispal, Patrick
Courtois, Roxanne
Winston, Brent W.
Reynolds, Steve
Birks, Peter
Bienvenue, Boris
Tadie, Jean-Marc
Talarmin, Jean-Phillipe
Ansart, Severine
Karna, Anusha
Kong, Julia
-
Funding
Funding for this research was provided by:
Academic Medical Organization of Southwestern Ontario
London Health Sciences Foundation
- License Information
-
More Information
Article History
Received: 11 December 2024
Accepted: 21 July 2025
First Online: 31 August 2025
Declarations
:
: This study was approved by the Western University, Human Research Ethics Board (REB #s 6970; #100036; # 6963). Our experimental methods are performed in accordance with ethical standards of the responsible committee on human experimentation with the Helsinki Declaration of 1975. Informed written consent was obtained from either participants or their legal guardians.
: Not applicable.
: Dr. Russell reports patents owned by the University of British Columbia (UBC) that are related to (1) the use of PCSK9 inhibitor(s) in sepsis, (2) the use of vasopressin in septic shock and (3) a patent owned by Ferring for use of selepressin in septic shock. Dr. Russell is an inventor on these patents. Dr. Russell is a shareholder in Molecular You Corp. Dr. Russell was a co-founder, Director and shareholder of Cyon Therapeutics Inc. (now closed) and Dr. Russell is currently a Cofounder, Director, and shareholder of Resolve Nanotherapeutics. Dr. Russell is the Senior Research Advisor of the British Columbia, Canada Post COVID – Interdisciplinary Clinical Care Network (PC-ICCN). Dr. Russell is no longer consulting for any industry. Dr. Russell reports receiving consulting fees in the last 3 years as a funded member of the Data and Safety Monitoring Board (DSMB) of an NIH-sponsored trial of plasma in COVID-19 (PASS-IT-ON) (2020–2021). Dr. Russell is the non-funded Chair of the Data and Safety Monitoring Board (DSMB) of a trial UC CISS II of stem cells in sepsis. Dr. Russell was a non-funded Science Advisor and member, Government of Canada COVID-19 Therapeutics Task Force (June 2020–2021). Dr. Russell has received grants for COVID-19 and for pneumonia research: 6 from the Canadian Institutes of Health Research (CIHR) and 3 from the St. Paul’s Foundation (SPF).
